AGIOS PHARMACEUTICALS, INC. Operating Cash Flow
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Operating Cash Flow of -$176.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-30
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$57.31M.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$118.92M.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$96.21M.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$88.15M.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$372.98M.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$389.84M.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$296.06M.
- AGIOS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$309.48M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$57.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$176.23M 10-Q · filed 2026-07-30 | -$272.44M derived: sum of 3 quarters · filed 2026-07-30 | -$360.60M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$118.92M 10-Q · filed 2026-04-29 | -$215.13M derived: sum of 2 quarters · filed 2026-04-29 | -$303.28M derived: sum of 3 quarters · filed 2026-04-29 | -$380.41M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$96.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$184.36M derived: sum of 2 quarters · filed 2026-02-12 | -$261.49M derived: sum of 3 quarters · filed 2026-07-30 | -$372.98M 10-K · filed 2026-02-12 |
| 2025-09-30 | -$88.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$165.28M derived: sum of 2 quarters · filed 2026-07-30 | -$276.76M 10-Q · filed 2025-10-30 | -$409.93M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$77.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$188.61M 10-Q · filed 2026-07-30 | -$321.78M derived: sum of 3 quarters · filed 2026-07-30 | -$406.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$111.49M 10-Q · filed 2026-04-29 | -$244.66M derived: sum of 2 quarters · filed 2026-04-29 | -$328.87M derived: sum of 3 quarters · filed 2026-04-29 | -$401.46M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | -$133.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$217.38M derived: sum of 2 quarters · filed 2026-02-12 | -$289.97M derived: sum of 3 quarters · filed 2026-02-12 | -$389.84M 10-K · filed 2026-02-12 |
| 2024-09-30 | -$84.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$156.81M derived: sum of 2 quarters · filed 2025-10-30 | -$256.67M 10-Q · filed 2025-10-30 | -$329.16M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | -$72.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$172.46M 10-Q · filed 2025-07-31 | -$244.94M derived: sum of 3 quarters · filed 2026-02-12 | -$306.59M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | -$99.87M 10-Q · filed 2025-05-01 | -$172.35M derived: sum of 2 quarters · filed 2026-02-12 | -$234.00M derived: sum of 3 quarters · filed 2026-02-12 | -$300.75M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | -$72.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$134.13M derived: sum of 2 quarters · filed 2026-02-12 | -$200.88M derived: sum of 3 quarters · filed 2026-02-12 | -$296.06M 10-K · filed 2026-02-12 |
| 2023-09-30 | -$61.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$128.39M derived: sum of 2 quarters · filed 2024-10-31 | -$223.57M 10-Q · filed 2024-10-31 | -$289.74M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | -$66.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$161.93M 10-Q · filed 2024-08-01 | -$228.09M derived: sum of 3 quarters · filed 2025-02-13 | -$299.44M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | -$95.18M 10-Q · filed 2024-05-02 | -$161.35M derived: sum of 2 quarters · filed 2025-02-13 | -$232.70M derived: sum of 3 quarters · filed 2025-02-13 | -$306.93M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | -$66.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | -$137.51M derived: sum of 2 quarters · filed 2025-02-13 | -$211.74M derived: sum of 3 quarters · filed 2025-02-13 | -$309.48M 10-K · filed 2025-02-13 |
| 2022-09-30 | -$71.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$145.58M derived: sum of 2 quarters · filed 2023-11-02 | -$243.31M 10-Q · filed 2023-11-02 | -$327.41M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | -$74.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$171.96M 10-Q · filed 2023-08-03 | -$256.06M derived: sum of 3 quarters · filed 2024-02-15 | -$341.24M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$97.73M 10-Q · filed 2023-05-04 | -$181.83M derived: sum of 2 quarters · filed 2024-02-15 | -$267.01M derived: sum of 3 quarters · filed 2024-02-15 | -$384.31M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$84.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$169.28M derived: sum of 2 quarters · filed 2024-02-15 | -$286.57M derived: sum of 3 quarters · filed 2024-02-15 | -$407.32M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$85.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$202.48M derived: sum of 2 quarters · filed 2022-11-03 | -$323.23M 10-Q · filed 2022-11-03 | -$372.62M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$117.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$238.04M 10-Q · filed 2022-08-04 | -$287.44M derived: sum of 3 quarters · filed 2023-02-23 | -$355.65M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$120.75M 10-Q · filed 2022-05-05 | -$170.15M derived: sum of 2 quarters · filed 2023-02-23 | -$238.35M derived: sum of 3 quarters · filed 2023-02-23 | -$306.15M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$49.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$117.60M derived: sum of 2 quarters · filed 2023-02-23 | -$185.40M derived: sum of 3 quarters · filed 2023-02-23 | -$290.76M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$68.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$136.00M derived: sum of 2 quarters · filed 2021-11-03 | -$241.36M 10-Q · filed 2021-11-03 | -$334.97M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$67.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$173.16M 10-Q · filed 2021-07-29 | -$266.77M derived: sum of 3 quarters · filed 2022-02-24 | -$352.36M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$105.36M 10-Q · filed 2021-04-29 | -$198.97M derived: sum of 2 quarters · filed 2022-02-24 | -$284.56M derived: sum of 3 quarters · filed 2022-02-24 | -$372.71M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$93.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$179.20M derived: sum of 2 quarters · filed 2022-02-24 | -$267.35M derived: sum of 3 quarters · filed 2022-02-24 | -$370.62M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$85.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$173.74M derived: sum of 2 quarters · filed 2020-11-05 | -$277.01M 10-Q · filed 2020-11-05 | -$351.20M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$88.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | -$191.42M 10-Q · filed 2020-07-30 | -$265.61M derived: sum of 3 quarters · filed 2021-02-25 | -$329.45M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$103.27M 10-Q · filed 2020-04-30 | -$177.46M derived: sum of 2 quarters · filed 2021-02-25 | -$241.30M derived: sum of 3 quarters · filed 2021-02-25 | -$308.69M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$74.19M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$138.03M derived: sum of 2 quarters · filed 2021-02-25 | -$205.42M derived: sum of 3 quarters · filed 2021-02-25 | -$304.42M 10-K · filed 2021-02-25 |
| 2018-09-30 | -$63.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | -$131.23M derived: sum of 2 quarters · filed 2019-10-31 | -$230.23M 10-Q · filed 2019-10-31 | -$304.69M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-06-30 | -$67.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$166.40M 10-Q · filed 2019-08-01 | -$240.85M derived: sum of 3 quarters · filed 2020-02-19 | -$318.56M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-03-31 | -$99.00M 10-Q · filed 2019-05-02 | -$173.45M derived: sum of 2 quarters · filed 2020-02-19 | -$251.17M derived: sum of 3 quarters · filed 2020-02-19 | -$310.16M derived: sum of 4 quarters · filed 2020-02-19 |
| 2017-12-31 | -$74.45M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | -$152.17M derived: sum of 2 quarters · filed 2020-02-19 | -$211.16M derived: sum of 3 quarters · filed 2020-02-19 | -$285.23M 10-K · filed 2020-02-19 |
| 2017-09-30 | -$77.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$136.70M derived: sum of 2 quarters · filed 2018-11-01 | -$210.78M 10-Q · filed 2018-11-01 | -$262.00M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-06-30 | -$58.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$133.06M 10-Q · filed 2018-08-02 | -$184.29M derived: sum of 3 quarters · filed 2019-02-14 | -$233.32M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-03-31 | -$74.07M 10-Q · filed 2018-05-04 | -$125.30M derived: sum of 2 quarters · filed 2019-02-14 | -$174.33M derived: sum of 3 quarters · filed 2019-02-14 | |
| 2016-12-31 | -$51.22M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | -$100.25M derived: sum of 2 quarters · filed 2019-02-14 | $38.56M 10-K · filed 2019-02-14 | |
| 2016-09-30 | -$49.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $89.78M 10-Q · filed 2017-11-01 | ||
| 2016-06-30 | $138.81M 10-Q · filed 2017-08-08 | |||
| 2015-12-31 | -$76.95M 10-K · filed 2018-02-14 | |||
| 2013-12-31 | -$13.62M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-18 | -$28.60M derived: sum of 2 quarters · filed 2014-03-18 | -$56.40M 10-K · filed 2014-03-18 | |
| 2013-09-30 | -$14.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$42.78M 10-Q · filed 2013-11-07 | ||
| 2013-06-30 | -$27.80M 10-Q · filed 2013-09-05 | |||
| 2012-12-31 | -$11.63M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-18 | -$23.03M derived: sum of 2 quarters · filed 2014-03-18 | -$49.55M 10-K · filed 2014-03-18 | |
| 2012-09-30 | -$11.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$37.92M 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | -$26.52M 10-Q · filed 2013-09-05 | |||
| 2011-12-31 | -$15.22M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |